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Abstract
Polytope approach of genetic immunization is a promising strategy for the prevention of infectious disease as it is capable
of generating effective cell mediated immunity by delivering the T cell epitopes assembled in series. Leishmaniasis is a
significant world wide health problem for which no vaccine exists. In this study we have compared immunogenicity and
efficacy of three types of DNA vaccines: single antigen Gp63 (Gp63/pcDNA), polytope (Poly/pcDNA) and Polytope fused
with hsp70 (Poly/hsp/pcDNA) against visceral leishmaniasis in susceptible BALB/c mice. Mice vaccinated with these plasmids
generated strong Th1 immune response as seen by dominating IFN-c over IL-10 cytokine. Interestingly, cytotoxic responses
generated by polytope DNA plasmid fused with hsp70 of Leishmania donovani were significantly higher when compared to
polytope and single antigen Gp63 vaccine. Challenge studies revealed that the parasite load in liver and spleen was
significantly lower with Poly/hsp/pcDNA vaccination compared to other vaccines. Therefore, our study indicates that
polytope DNA vaccine is a feasible, practical and effective approach for visceral leishmaniasis.
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Introduction
Poly-epitope based DNA immunization approach has an
excellent ability to induce T cell responses. Polytope DNA vaccine
encodes multiple continuous T cell epitopes which induce specific
Cytotoxic T lymphocyte (CTL) responses or T helper (Th)
responses to individual epitope. Earlier studies have shown that
each epitope in polytope constructs is processed, presented and is
immunogenic in animals with an appropriate MHC back-
ground[1]. The polytope approach allows epitopes restricted by
a range of different MHC alleles to be combined, making feasible
the construction of epitope based vaccines that cover wider HLA
diversity of the target population[1]. Experimental Polytope
vaccines have been developed for number of pathogens such as
HIV/AIDS, HBV and cancers[2–6]. The main advantage of this
strategy is its ability to eliminate portions of the antigen that may
cause harmful immune responses[7]. Malarial parasites exhibit
certain regions that may decoy responses thereby eliciting
antibodies of irrelevant specificities and diverting protective
responses. Gilbert et al[8] generated a polytope vaccine against
Plasmodium Sps. that contained a string of 15 defined cytotoxic T
lymphocyte (CTL) epitopes from Plasmodium species which primed
protective CTL responses in mice following a single administration
without adjuvant. The immunogenicity of HIV polytope vaccine
containing multiple HLA A2 HIV CD8+ cytotoxic T-cell epitopes
was shown by Woodberry et al[9].
Visceral Leishmaniasis (VL) is a major public health problem
with significant morbidity and mortality worldwide[10]. Cellular
immune mechanisms are critical for recovery from VL and for
protectionfrom re-infectionin both human and mice[10]. Although
leishmanial infections induce strong humoral responses, the role of
the elevated antileishmanial antibodies in kala-azar patients towards
protection and pathogenesis is still unclear[11]. An experimental
study postulated that IgG not only fails to provide protection against
this intracellular pathogen, but it actually contributes to disease
progression[12,13]. Passive administration of antileishmanial IgG
antibodies resulted in larger lesions in Balb/c mice with greater
amount of IL-10 production[12]. Thus, it appears that anti-
leishmanial antibodies or humoral immunity does not play a
protective role in the control of the disease.
Early classical experiments established that CD4+ T cells are
crucial for resistance, whereas CD8+ T cells seem to participate
more in generation of immune memory and as effector cells for
parasite elimination[14]. However, recent studies have suggested
that CD8+ T cells may be involved in the clearance of primary
infection[15]. In rodent models, the Th1/Th2 paradigm is
important in determining the outcome of murine L. major
infection[16]. This dichotomy is not well demarcated during
murine L. donovani/L. chagasi infection in which curative type1
responses may be suppressed by IL-10 and TGF-b [17]. Protective
immunity against VL as in case of CL (Cutaneous leishmaniasis) is
dependent on IL-12 driven type1 response characterized by IL-2
and IFN-c production, which results in the induction of parasite
killing[18]. Regarding immune responses in human acute visceral
leishmaniasis, the cytokine profile is high production of IL-4 and
IL-10 and low IL-2 and IFN- c production[19].
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potential of peptides as immunogens for CTLs. These include the
demonstration that CTLs can recognize small antigenic peptides
of 8–10 amino acids in length, which complexed with MHC class I
molecules and are expressed on the surface of infected or cancer
cells to be presented to T-cell receptors[20,21]. Targeting of
dominant epitopes may be an effective way to overcome CTL
tolerance [22] and to allow the immune response to focus on
highly conserved epitopes[23].
The best candidates for designing a vaccine are the proteins
required for parasite survival or adhesion of parasites to host cells,
have low mutation rates and have conserved epitopes. Gp63, a
glycoprotein of 63 kilo Dalton that occurs on the surface of
Leishmania was the first candidate from Leishmania major used for
DNA vaccine[24]. It has been demonstrated earlier that L. donovani
contains more chromosomal mini-exon gene sequences than L.
major which contribute to its increased virulence[25]. The structure
of gp63 gene of L. donovani contains 7 tandem repeats and each
repeat contains 1.8 kb coding region and 1.3 kb intergenic
region[26]. Russo et al[27] has identified human T cell epitopes
in both L.major and L. chagasi gp63. Some of these T cell epitopes
induced proliferative and IFN-c responses in cells from infected
individuals. Two of the peptide epitopes from L. major and L. chagasi
gp63 were capable of generating Leishmania specific T cell lines
invitro[27]. We have identified corresponding 2 human T cell
epitopes and 7 murine T cell epitopes in the coding region of
Leishmaniadonovani,Gp63 gene (M60048)using NCBIBLAST (Basic
Local Alignment Search Tool). In the present study, a polytope
DNA vaccine was prepared using these two immunogenic human T
cellepitopesofLeishmaniadonovani,Gp63 genewhichwere analogous
to the epitopes identified by Russo et al, [27] in L.major and L. chagasi
gp63 gene. Out of these two immunogenic human T cell epitopes,
one is both human as well as murine T cell epitope [27].
Srivastava et al[28] have demonstrated that heat shock protein
(hsp) strongly enhances the immune reaction to tumor-associated
antigens. Several studies showed that hsp70 isolated from tumor
cells was able to induce specific CTL responses capable of
protecting against tumor growth and viral infection [29].
Mycobacterium tuberculosis hsp70 has been found to be a powerful
antigen containing multiple B- and T-cell epitopes and to induce
CTL response in dendritic cells in a CD4 Th-independent
manner[3]. In fact, Suzue et al [30] produced and purified a
recombinant HIV-I p24-hsp70 fusion protein and demonstrated
that it could elicit both humoral and cellular responses against
HIV-1 p24 in the absence of adjuvant[31]. The MHC class I in
conjunction with hsp70 has been shown to generate CTL
responses[32]. Wang et al[33] suggested that CD40 was a cellular
receptor for TBhsp70. The CD40/CD40L interaction also leads
to production of inflammatory cytokines, such as TNF-a, IL-1, IL-
6, IL-12 and RANTES [34]. Indeed, recent studies demonstrated
a central role for ligation of CD40 on macrophages and dendritic
cells in the induction of MHC class I-restricted antigen specific
CD8+ T-cell responses and protective immunity[35].
In the present study, three vaccine formulations i.e. single
antigen Gp63 DNA vaccine (coding region of Gp63 gene of
L.donovani), Polytope DNA vaccine and Polytope DNA vaccine
fused to hsp70 molecule of Leishmania donovani were compared for
their immunogenicity and efficacy in a mouse model.
Materials and Methods
Animals
3–4 weeks old, female BALB/c mice weighing 15–18 gm were
obtained from the Central Animal Facility, National Institute of
Pharmaceutical Education and Research, Mohali, India. All
animals were housed and used in the departmental animal house
in accordance with institutional guidelines.
The study was reviewed and approved by the Institute Ethical
Committee of Postgraduate Institute of Medical Education and
Research, Chandigarh, India.
Culture of Leishmania promastigotes
AG83 strain of Leishmania donovani was used in the present study.
The parasite was passaged in BALB/c mice before the
experiments to maintain the virulence. The amastigotes obtained
from spleens of BALB/c were suspended in DMEM with 30%
Fetal Calf Serum (FCS). This suspension was incubated at 22uC
for 48 to 72 h. Freshly transformed promastigotes were checked
under the microscope for their morphology and number. The
suspension was centrifuged at 1000 rpm for 10 min at 4uCt o
remove splenic debris and promastigotes were pelleted down at
5000 rpm for 15 min at 4uC. These promastigotes were
maintained in DMEM with 10% FCS at 22uC. Subculturing
was done on every fourth day when the promastigotes attained
stationary phase of growth.
Cloning and expression of Gp63 gene
PCR cloning was carried out after PCR amplification of coding
region of Gp63 gene of Leishmania donovani using following pair of
primers.
forward 59 GCA GCC GGA TCC ATG TCC GTC GAC
AGC AGC AGC 39
reverse 59 GCG GCC AAG CTT CAC GCC ATC ACC ACC
CGT CCT 39
The 1.8 kb PCR product obtained was digested with BamHI
and HindIII and ligated into pET-30a vector (Novagen, Madison,
USA) for Recombinant Protein and into pcDNA3.1 vector
(Invitrogen, USA) for DNA vaccine. The ligated product was
transformed into E. coli BL21 and DH5a cells respectively for
pET30a vector and pcDNA3.1 vector. Transformants were
analyzed by restriction digestion and the positive clone was
sequenced to confirm the presence of Gp63 insert in proper
reading frame (Data S1). The positive clones were designated
pET30/Gp63 and pcDNA/Gp63. Transformed BL-21 cells were
amplified by growing on LB broth medium supplemented with
50 mg/ml kanamycin. The transformed cells were grown to log
phase (OD600=0.6 to 1.0) and IPTG was added to a final
concentration of 0.4 mM. The culture was grown at 37uCi na
shaker incubator and 1 ml aliquots were collected at each hour.
The same number of cells from each aliquot was loaded on an
SDS-PAGE gel and checked for recombinant protein expression
(pET-system manual, 1992, Novagen, Madison, USA).
The invitro expression of the inserted Gp63 gene in eukaryotic
expression vector pcDNA3.1 was checked by transfection of gp63/
pcDNA construct in mammalian cells i.e. 293 cells & J774A.1
macrophage cells. The expression was confirmed by Qualitative
reverse transcription PCR (RT-PCR). Total RNA was isolated
from the transfected cells using TRIZOL reagent (Invitrogen,
USA) according to manufacturer’s instructions. RT-PCR was
performed using RT-PCR kit (Promega, Madison, USA) using
3 mg of each of the RNA sample.
Purification of recombinant GP63 (rGP63) protein by urea
gradient
The induced E. coli (BL21) culture cells were collected and
resuspended in 10 ml of TNE (Tris-Cl, NaCl, EDTA) buffer
followed by addition of 10 mg of lysozyme. It was then kept on ice
Polytope DNA Vaccines
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sat 4uC and pellet and supernatant fractions were separated. The
induced protein was found to be in the pellet fraction. The pellet
was treated for purification of recombinant Gp63 protein by urea
gradient method using 2 M, 4 M and 8 M urea concentrations as
described by Sukumaran et al[36]. The positive fractions were
identified by SDS-PAGE and dialysed extensively against slowly
decreasing concentrations of urea in PBS. Protein was further
purified and concentrated by using Centricon-30 filters (Amicon,
USA).
Preparation of DNA vaccines
Single antigen DNA vaccine. The coding region of gp63
gene of Leishmania donovani (1.8 kb) cloned in pcDNA3.1 plasmid
was used as single antigen DNA vaccine.
Polytope DNA vaccines. pcDNA3.1(2) vector was used to
construct polytope DNA vaccine plasmids. The T cell epitopes
included in the vaccine were: two immunogenic gp63 T cell
epitopes PT1 and PT7 which we have identified in AG83 strain of
L. donovani and one universal Th Pan DR epitope [(PADRE)
sequence] [3]. PADRE is a synthetic Th epitope engineered by
introducing anchor residues for the different DR motifs of MHC II
into a polyalanine backbone[37] and the resulting peptide binds a
variety of DR molecules as well as certain mouse class II alleles,
including I-Ab, I-Ed and I-Ek. Each epitope was separated by
AAA nucleotides encoding lysine. This artificial polytope antigen
also contained IgG k chain leader sequence (used as a signal
peptide) and a Kozak sequence which was inserted at the 59-
terminal of signal peptide as the ribosome-binding site[3]. The
whole designed sequence was divided into seven equal fragments,
averaging 75 nucleotides in length (Fig. 1A). The primers were
designed with 15 oligonucleotide overlaps between consecutive
fragments. These seven fragments were spliced together using the
primers by overlap extension and PCR techniques (Li et al 2005)
to obtain a final polytope antigen gene (Fig. 1A). All the oligomers
and primers were synthesized commercially with 2–5 OD (40 nm)
and were machine grade purified.
For enhancing CTL activity, hsp70 gene of Leishmania donovani
was fused to the C-terminal of polytope antigen gene and was
inserted into the pcDNA vector[34]. Hsp70 gene was amplified
from genomic DNA of Leishmania donovani using following pair of
primers:
Forward primer
59 CGG CTT CTG CTG GCT TTG GTG CTG GCT TTG
GTT TGG TAC CAT
GAC ATT CGA CGG CGC C 39
Reverse primer
59 CCC AAG CTT GGG TTA GTC GAC CTC CTC GAC
CTT 39
BamHI, KpnI and HindIII restriction sites were included in the
primers for cloning purposes. The positive clones were confirmed
by restriction digestion with the respective enzymes (Fig. 1C). Both
the constructs i.e. Polytope/pcDNA and Polytope/Hsp/pcDNA
were sequenced to confirm the correct orientation of the
introduced sequences. The plasmid preparation for immunization
experiments was undertaken by using the EndoFree Plasmid Giga
kit (Qiagen, Germany). The DNA purified with EndoFree plasmid
kits contains only negligible amounts of endotoxin (,0.1 EU/mg
plasmid DNA).
Immunization Schedule
Immunization schedule followed was as reported earlier by
Yang et al [38] with slight modifications. A total of 18 mice were
used for each vaccination and control group1 while 12 mice were
employed as normal controls (control group 2) for both
immunological and parasitological assays.
As illustrated in table 1, there were 3 parenteral DNA vaccines
used in the study i.e. single antigen Gp63 DNA vaccine (Gp63/
pcDNA - groups 1, 2), Polytope DNA vaccine (Polytope/pcDNA-
groups 3, 4) and Polytope DNA vaccine fused with hsp molecule
(Polytope/hsp/pcDNA-groups 5, 6) which were administered
intramuscularly [24] in three doses of 100 mg each at weekly
intervals followed by a final booster on day 21 with the respective
DNA vaccine constructs to groups 1, 3 & 5 and with recombinant
Gp63 protein by intraperitoneal route [39] to groups 2, 4 & 6.
Two control groups were included: Control group 1 included
vector plasmid pcDNA alone while Control group 2 comprised of
un-inoculated healthy mice as normal controls.
Immunogenicity assays
The Immunogenicity of vaccines was studied by splenocyte
proliferation, cytokine production and cytotoxicity assays. All the
assays were performed on post immunization days 21, 35 and 63
(4 weeks after challenge) in all the groups of animals as described
in Table 1. To see the effect of challenge infection on
immunological parameters, unchallenged mice in each vaccine
group were also included on day 63.
Splenocyte proliferation assay
Spleens were removed from mice under aseptic conditions on a
sterile dish containing DMEM medium. Single cell suspensions were
prepared by grinding the spleen using an autoclaved mesh. 5–10 ml
of DMEM medium was added to it and the contents were mixed to
homogeneity. The dish was kept undisturbed for two minutes and the
clear supernatant was pipetted out slowly. Cells were pelleted by
centrifugation at 4uC at 250 g (Sorvall RC-5 centrifuge, HB-4 rotor)
for 10 min. The pellet containing erythrocytes and splenocytes were
collected. The pellet was washed once with 0.9% ammonium
chloride to lyse the erythrocytes. The remaining cells i.e. splenocytes
from each mouse in a group were pooled were resuspended to a
density of 2.5610
6 cells/ml in DMEM containing 10% FCS and
0.05 mM 2-mercaptoethanol, then divided into 200 ml aliquots
(5610
5 cells) in 1.5 ml eppendorf tubes. The splenocytes were re-
stimulated with 1, 5, 10 mg recombinant GP63 antigen (rGP63
protein vaccine). These cells were incubated for 3-days at 37uCi n
atmosphere containing 5% CO2 and 95% humidity. Proliferation
was measured by incorporation of 1 mCiof [
3H]-thymidine over final
16 h of the 3 days of culture. The cells were harvested and taken in
scintillation vials, scintillation fluid was added and counts were taken.
Stimulation indices (S.Is) were calculated as the ratios of [
3H]-
t h y m i d i n ei n c o r p o r a t i o ni nt h ep r e s e n c eo fa n t i g e nv e r s u st h en o n -
stimulated (medium alone) control. All assays were performed in
triplicate, with four mice representing each group.
Cytokine determination
IFN-c, IL-2, IL-4 and IL-10 concentrations in cell culture
supernatants were determined using CBA flex kit (BD Biosciences,
Singapore) according to manufacturer instructions. The results
were acquired using FACS CALIBUR (BD Biosciences, Singa-
pore) and analyzed using FCAP software.
Invitro cytotoxicity assays
Parasitized J774A.1 macrophage cells were used as target cells
for the cytotoxicity assays. Macrophages were grown and plated at
2610
5/ml in six-well plates in Dulbecco MEM containing 10%
FCS. Adherent cells were harvested on ice, and infected with late
stationary phase L. donovani promastigotes. For infection, 10
5
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for 1 h at RT to give a multiplicity of infection of 2 to 4 parasites
per cell. At the end of infection, non-internalized parasites were
separated from macrophages by washing with PBS. An aliquot of
infected macrophages was stained with Giemsa to check the level
of infection. Infected cells (10
6 cells/ml) were also incubated with
propidium iodide (100 mg/ml), a fluorescent dye which is excluded
by viable cells and stains non-viable cells as red. Another dye
fluorescein diacetate (FDA) which stain the viable cells showed
green fluorescence when cells were incubated with 100 ng/ml of
dye for 10 min at room temperature [40]. Microscopic examina-
tion verified that 70% of macrophages contained viable parasites.
Cytolytic activity of splenocytes was evaluated by measuring
lactate dehydrogenase (LDH) activity released into the medium,
using the CytoTox96 nonradioactive assay (Promega, Madison,
WI, USA) according to manufacturer instructions. Briefly, the
Figure 1. Construction of vaccine plasmids for DNA vaccination. (A) Polytope Vaccine design: The DNA sequence coding for the polytope
antigen contained Kozak sequence, IgG k leader sequence, PADRE sequence and two T cell epitopes. Each epitope was separated with AAA
nucleotides encoding lysine. This polytope gene was made by joining seven overlapping oligonucleotides using splicing by overlap extension and
PCR and was cloned into BamHI and kpnI restriction sites of pcDNA3.1 vector. The Poly/pcDNA encoded Polytope antigen (Polytope DNA vaccine),
Poly/hsp/pcDNA encoded hsp70-fused polytope antigen (Poly/hsp DNA vaccine). (B) Nucleotide sequence of final product of Polytope DNA which
showed 100% homology to designed sequence. (C) Restriction digestion of vaccine plasmid constructs to confirm the presence of insert gene
sequences. (D) SDS-PAGE (12%) analysis of invitro expression of Polytope antigen fused with hsp70 in J774A.1 macrophages and 293 cells.
doi:10.1371/journal.pone.0007880.g001
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splenocytes (effector cells) previously isolated at different time
intervals from various vaccinated and unvaccinated groups of mice
and stimulated with rGp63 protein and concanavalinA (Control).
The effector (E) and target (T) cells were incubated for 4 h at E/T
ratio of 1:10. Cell lysis was determined by LDH release and it was
quantified by measuring the absorbance at 490 nm. Maximum
release was calculated from supernatants of cells that were lysed by
addition of 10 ml of lysis solution (10x). The effector and target
cells were included as separate controls for spontaneous release.
The percentage of specific lysis was calculated as follows:
[(Experimental – Spontaneous release)/(Total maximum release
- Spontaneous release)] 6100.
Protection studies
The efficacy of the vaccine preparations was determined by
challenge infection of vaccinated and unvaccinated control mice
with 2610
7 Leishmania donovani promastigotes intravenously, 2 weeks
after the booster dose (day35, Table-1). The parasite loads in liver
and spleen were determined after 4 weeks of challenge infection.
Determining organ parasite load
After 4 weeks of challenge infection, mice were euthanized. The
liver and spleen were aseptically removed and their impression
smears were microscopically examined after fixing and staining the
slides with Giemsa. In order to quantitate levels of infection,
Leishman Donovan units (LDU) were calculated as: Number of
amastigotes/Number of cell nuclei X weight of organ in
milligrams [39]. Protection studies were performed using 6 mice
per group. Results were evaluated by comparing the parasite load
of test and control groups of mice.
Statistical analysis
Data are expressed as the mean values 6 S.D. of triplicate
samples. The statistical significance of the differences between
various groups was determined by PostHoc test and ANOVA.
Differences were considered statistically significant for p,0.05.
Results
Epitope selection and vaccine plasmid construction
The single antigen Gp63 DNA (Gp63/pcDNA) and polytope
(Poly/pcDNA, Poly/Hsp/pcDNA) vaccines were constructed as
described above and used for DNA vaccination (Fig. 1A).
The Polytope vaccine preparations on sequencing showed
100% sequence identity with designed vaccine (Fig. 1B) which
confirmed the correct orientation of the introduced sequences.
The positive clones were confirmed by restriction digestion with
respective enzymes (Fig. 1C). The prominent products of expected
molecular masses 63kDa and 92kDa were expressed by eukaryotic
cells (J774A.1 macrophages and 293) transfected with the plasmids
Gp63/pcDNA and Polytope/Hsp/pcDNA (Fig. 1D) respectively
but not by pcDNA3.1 vector transfected cells.
Immunogenicity assays
For comparison of immunological and efficacy parameters
between various vaccine groups and unvaccinated (control)
groups, for control group the values of only PBS groups were
included in the analysis as the values of pcDNA vector controls
were not significantly different from that of PBS controls.
Splenocyte Proliferation assay
Splenocytes from all the vaccinated mice showed significantly
higher proliferation than that of control group on all study days
(day 21, 35 and 63) and highest response was seen with Poly/Hsp
vaccine on day63 in unchallenged mice (p=0.0001) (Fig. 2).
Amongst challenged animals, the proliferative index on day 63 was
highest in single antigen Gp63 DNA vaccine groups (Fig. 2).
Protein boost significantly enhanced the stimulation index for
Polytope DNA vaccine group (Poly/PB) on day35 (p=0.001) but
not in other two vaccine formulations (p.0.05) (Fig. 2).
Cytotoxicity assay
In order to detect the cytolytic activity of splenocytes isolated
from all the vaccinated groups of mice on day21, 35 and day63
(challenged & unchallenged), we tested their capacity to lyse the
Leishmania donovani infected macrophage cells. Substantial levels of
cytotoxicity were detected only in vaccinated animals (Fig. 3).
There was no significant difference in the cytotoxicity of
splenocytes on days 21 and 35 for single antigen Gp63 DNA
and Polytope vaccine groups (Fig. 3). The Poly/hsp vaccine group
showed highest cytotoxicity (85%) on day 63 (after 4 weeks of
challenge infection) which was followed by Gp63 DNA vaccine
(72%). In unchallenged mice on day63, polytope/hsp vaccine
group showed significantly higher cytolytic activity compared to
polytope group (p,0.01) but there was no significant difference in
cytotoxicity between polytope/hsp and Gp63 DNA vaccine
groups (Fig. 3). Protein boosting for Poly/DNA vaccine group
Table 1. Vaccination schedule for immunogenicity and efficacy studies in BALB/c mice.
Time of
Immunization
And Challenge
Group 1
Gp63 DNA
Group 2
Gp63/PB
Group 3 Poly
DNA
Group 4
Poly/PB
Group 5
Poly/Hsp
Group 6
Poly/Hsp/PB
Control group
1p c D N A
Normal
Control
group 2 PBS
0d a y( 1
st dose) Gp63/pcDNA
(100 mg) (i.m.)
Gp63/pcDNA
(100 mg) (i.m.)
Polytope/pcDNA
(100 mg) (i.m.)
Polytope/pcDNA
(100 mg) (i.m.)
Polytope/hsp/pcDNA
(100 mg) (i.m.)
Polytope/hsp/pcDNA
(100 mg) (i.m.)
Vector plasmid
100 mg( i . m . )
PBS
7
th day (2
nd dose) Gp63/pcDNA
(100 mg) (i.m.)
Gp63/pcDNA
(100 mg) (i.m.)
Polytope/pcDNA
(100 mg) (i.m.)
Polytope/pcDNA
(100 mg) (i.m.)
Polytope/hsp/pcDNA
(100 mg) (i.m.)
Polytope/hsp/pcDNA
(100 mg) (i.m.)
Vector plasmid
100 mg( i . m . )
PBS
14
th day (3
rd dose) Gp63/pcDNA
(100 mg) (i.m.)
Gp63/pcDNA
(100 mg) (i.m.)
Polytope/pcDNA
(100 mg) (i.m.)
Polytope/pcDNA
(100 mg) (i.m.)
Polytope/hsp/pcDNA
(100 mg) (i.m.)
Polytope/hsp/pcDNA
(100 mg) (i.m.)
Vector plasmid
100 mg( i . m . )
PBS
21
st day (Booster) Gp63/pcDNA
(100 mg) (i.m.)
Recombinant
Gp63 protein (i.p)
Polytope/pcDNA
(100 mg) (i.m.)
Recombinant Gp63
protein (i.p.)
Polytope/hsp/pcDNA
(100 mg) (i.m.)
Recombinant Gp63
protein (i.p.)
Vector plasmid
100 mg( i . m . )
PBS
Challenge 35
th day
(2weeks after
booster)
2610
7
promastigote
(i.v.)
2610
7
promastigote
(i.v.)
2610
7
promastigote
(i.v.)
2610
7
promastigote
(i.v.)
2610
7
promastigote (i.v.)
2610
7
promastigote (i.v.)
2610
7
promastigote
(i.v.)
2610
7
promastigote
(i.v.)
doi:10.1371/journal.pone.0007880.t001
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(Fig. 3). On the contrary, there was no significant effect of protein
boost on single antigen Gp63 DNA and Poly/Hsp vaccinated
groups.
Cytokine responses
The cytokine responses in splenocytes were analyzed for each of
the vaccine formulations (Fig. 4). Our results revealed a massive
up-regulation of IFN-c in cells isolated from vaccinated mice.
Gp63 DNA vaccine elicited significant IFN-c response on day
21which further increased on day 35. However, in this vaccine
group, there was no significant increase in IFN-c levels on day 63
in both challenged and unchallenged animals as compared to day
35 levels. Protein boosting significantly enhanced IFN-c levels on
day 35 & day 63 in challenged group for Gp63 DNA vaccine when
compared with non-protein boost group. On day21, Poly/Hsp
vaccine showed maximal IFN-c levels (p=0.0001) which declined
massively on day35. Protein boost significantly enhanced IFN-c on
day 35 for Poly DNA vaccine group (p=0.01). On day 63 in both
challenged and unchallenged group, Poly/Hsp and Poly/Hsp/PB
showed significantly higher levels (p=0.001 to 0.0001) of IFN-c
compared to Poly DNA and Poly/PB groups (Fig. 4A).
Significant levels of IL-2 were seen increased on day 21 in Gp63
DNA vaccine group and on day 35 in Gp63/PB group. In
contrast, IL-2 levels were almost undetectable after challenge
infection. Polytope DNA vaccines with hsp70 showed significant
IL-2 levels on all the days except on day 63 in challenged animals
whereas Poly DNA vaccine without hsp70 showed significantly
low IL-2 on day 63 both in challenged and unchallenged group.
Protein boost significantly enhanced these levels on day 35 for
both Gp63 DNA and both Polytope DNA vaccines (Fig. 4B).
Basal levels of IL-10 in PBS control group were significantly
high after 28 days of challenge infection (on day 63) as compared
on day 21 and 35. Significant levels of IL-10 were detected on day
21 and 35 in Gp63 DNA vaccinated groups but not in both the
polytope vaccinated groups. After challenge infection, rise in IL-10
cytokine was significantly lower in protein boost group of Gp63
DNA vaccinated animals. In case of Polytope DNA vaccines,
though IL-10 increased after challenge infection but these levels
were significantly low as compared to control group. There was no
effect of protein boost on IL-10 levels in Poly/Hsp vaccine group
(Fig. 4C).
In control (PBS) group, IL-4 levels on day 21 and 35 ranged
from 32 to 50 pg/ml but on challenge infection, IL-4 levels were
significantly enhanced. IL-4 cytokine levels were significantly low
after challenge infection in all vaccine groups when compared to
basal levels (controls) (p=0.0001 to 0.007) minimum being in
Poly/Hsp/PB and Poly/PB vaccinated groups. There was
increase in these levels in unchallenged group on day63 for all
the polytope vaccine groups and protein boosting did not
significantly affect these levels (Fig. 4D).
Parasite Load determination
Efficacy of all the vaccine formulations was checked by
determining the parasite load in both spleen and liver (Fig. 5).
There was significant decrease in parasite load in both spleen and
liver (p=0.001 to 0.0001) after challenge infection in all the
vaccinated groups for both single antigen and Polytope DNA
vaccines when compared to the unvaccinated groups. But when all
the vaccinated groups were compared, the parasite load was
significantly lower in liver for Poly/Hsp vaccine group as
compared to all other vaccinated groups. The parasite load in
spleen was similar in all the vaccinated groups, minimum being in
Poly/Hsp group which was significantly lower than that in Poly
DNA (p,0.05). Protein boosting in any vaccination group did not
significantly affect the efficacy of vaccines in terms of parasite load
in both liver and spleen.
Discussion
We demonstrate in our present study that epitope-based DNA
vaccination represents a new vaccine strategy for Leishmania
infection because of its excellent ability to induce T cell responses.
DNA vaccine coding multiple continuous CTL or Th epitopes can
induce specific CTL and Th responses to individual epitopes from
different antigens[41,42]. In our study, polytope DNA vaccine
containing two T cell epitopes from Gp63 gene of Leishmania
donovani and one universal Th epitope induced strong Th1
Figure 3. Percentage cytotoxicity of splenocytes isolated from
various groups of immunized and control BALB/C mice. The
splenocytes (Effector cells) were co-cultured with parasitized macro-
phages (Target cells) and cytotoxicity was measured as LDH release by
spectrophotometric analysis. Statistically significant difference was seen
in all the vaccinated groups when compared with controls (p,0.01).
The results presented here are the mean values obtained from LDH
release assay performed in triplicates.
doi:10.1371/journal.pone.0007880.g003
Figure 2. Splenocyte proliferation assay was performed on day
21, 35 and 63 following immunization and challenge infection
in BALB/c mice. The mice were immunized with Gp63 single antigen
DNA vaccine (Gp63/pcDNA) referred to as Gp63 DNA, Polytope DNA
vaccine (Poly/pcDNA) referred as Poly DNA and Polytope/Hsp DNA
vaccine (Poly/Hsp/pcDNA) referred as Poly/Hsp, thrice at weekly interval
with and without rGp63 protein boosting as described in Materials and
Methods. Splenocytes were stimulated with rGp63 protein or ConA
(data not shown) and thymidine incorporation was determined.
Stimulation Index represents the average counts per minute in
stimulated cells divided by the average counts per minute in
corresponding non-stimulated controls. The data is the mean of three
experiments.
doi:10.1371/journal.pone.0007880.g002
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antigen Gp63 DNA vaccination. Walker et al[43] showed that
genetic immunization with glycoprotein63 cDNA from L.major
resulted in Th1 immune response and protection in murine model
of leishmaniasis. As reported by Button et al[44], L. donovani
contains more chromosomal mini-exon gene sequences than L.
major and this appears to be associated with increased virulence.
Also VL (Kala azar) caused by L. donovani is a public health
problem in several states of India. Therefore, we chose Gp63 of
Leishmania donovani for the vaccine formulation. Curry et al[45]
showed that PT7 epitope of GP63 of L. major stimulated IFN-c
production in majority of vervet monkeys recovered from L.
donovani infection and IL-2/IL-4 production in all these animals.
The present study shows that the two immunogenic epitopes in the
coding region of Gp63 gene of Leishmania donovani, PT1 & PT7 [27]
used for the preparation of polytope DNA vaccines induced Th1
type of immune response and strong cytotoxic responses. We
believe that the stronger cytotoxic responses along with the higher
IFN- c levels generated by polytope/hsp DNA vaccine in our
study may be attributed to CD8+ T cells of spleens isolated from
Figure 4. IFN-c, IL-2, IL-4 and IL-10 production on day 21, day 35 and day 63 in all the vaccinated and control groups (6 mice per
group) as shown in Fig. 2. Culture supernatants were collected and the cytokines were assayed by flow cytometry. Results presented represent
the mean 6 SD (vertical lines on bars) of the triplicate assays.
doi:10.1371/journal.pone.0007880.g004
Figure 5. Parasite load in liver and spleen. All the vaccinated and
control groups (as described in Fig. 2) were challenged intravenously
(i.v.) with 2610
7 Leishmania donovani promastigotes on day35. Four
weeks after the challenge, mice were sacrificed and Leishman Donovan
units (LDU) were calculated from liver and spleen impression smears.
The mean LDU 6 SE is shown (n=6) mice per group.
doi:10.1371/journal.pone.0007880.g005
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to lyse Leishmania infected J774A.1 macrophages invitro. The
perforin dependent pathway of cytotoxicity could have mediated
this cytolytic activity of splenocytes particularly of CD8+ T cells
which have been shown to be functioning in visceral leishmaniasis
by Tsagozis et al[46]. Therefore, polytope vaccine approach
provides an ideal strategy to improve the DNA vaccine’s
prophylactic efficacy. In our study, hsp70 molecule was used as
genetic adjuvant to improve T cell responses since it has both
cytokine and chaperone functions[47]. Li et al [3] showed that
hsp70 was an intrinsic adjuvant molecule for polytope HBV DNA
vaccine. Basu et al [48] showed in H-2b and H-2d mice models
that hsp utilized the CD91R to be internalized by antigen-
presenting cells (APCs), and the complexes of peptides with hsp90,
calreticulin and hsp70 were also taken up by macrophages and
dendritic cells and represented by MHC class I molecules
Therefore, we assume that the hsp70-fused polytope antigen was
internalized by receptor-mediated endocytosis and APCs present-
ed the hsp-associated peptides, via their cell surface MHC class I
molecules, to CD8+T cells; thus, antigen presenting function was
improved. Interestingly, in present study the polytope DNA
vaccine fused with hsp70 gene of Leishmania donovani provided an
effective preventive strategy for visceral leishmaniasis as it
enhanced the cytolytic activity of splenocytes isolated from
vaccinated BALB/c mice and induced strong Th1 responses.
IL-10 is a major cytokine involved in progression of Leishmania
infection to visceral disease[49]. IL-10 has been shown to block
Th1 activation and consequently a cytotoxic response by down
regulating IFN-c levels and also because IL-10 inhibits macro-
phage activation, it decreases the ability of these cells to kill
Leishmania[50]. Studies in humans on tissue cytokine mRNA
expression have revealed that IL-10 is also involved in down
regulating CD4+ T cell responses and disease pathology of L.
donovani infections[51]. Because IL-10 usually exhibits human
macrophage deactivating properties, high levels of IL-10 may
represent a necessary counterbalance to an extremely polarized
immune response thereby limiting the tissue damage[52]. In our
study, though there was an increase in IL-10 levels after challenge
in Poly and Poly/Hsp vaccine groups, the ratio of IFN-c: IL-10
was still higher indicating the dominance of Th1 immune
response.
As hypothesized, the polytope vaccine using hsp70 as an
intrinsic adjuvant molecule resulted in significant reduction in
parasite load after 4 weeks of challenge infection. To summarize,
in the present study, both single antigen Gp63 DNA vaccine and
polytope DNA vaccines with and without hsp molecule were
found to be highly immunogenic as seen by splenocyte
proliferation, cytotoxicity & cytokine production in vaccinated
and control balb/c mice. Recombinant Gp63 protein boost
enhanced the immunogenicity of single antigen Gp63 DNA
vaccine as there was significant increase in Stimulation Index,
Cytotoxicity and Th1 cytokine levels. There was no affect of
protein boost on Polytope DNA vaccine. Both the vaccines showed
significant efficacy against the challenge parasitic infection as seen
by reduction in parasite load in balb/c mice. However, protein
boost in any vaccine did not significantly enhanced the efficacy.
When all the vaccines were compared, Polytope DNA vaccine
with hsp70 showed highest Immunogenicity and efficacy.
To the best of our knowledge, this is the first study on polytope
DNA vaccine for visceral leishmaniasis. Furthermore, we have
successfully used the hsp70 gene from the same parasite species (L.
donovani) in a polytope DNA vaccine while most previous studies on
polytope DNA vaccines have employed hsp gene of mycobacte-
rium or cancer cells[33,53].
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